CTSD and neuroblastoma: First, we searched for the pediatric neuroblastoma patients (TARGET 2018) available in the TCGA portal to monitor the mutation profiles and mRNA expression of MYCN, EGFR, EGF, MAPK1 and CTSD. The oncoprint (Figure 1A, upper part) shows that out of 248 pediatric neuroblastoma patients, MYCN was amplified in 11 patients, and a missense mutation was found in 3 patients (1%).